News & Press Releases Swedish

Scandinavian ChemoTech deltar och presenterar på LSI Emerging Medtech Summit i Kalifornien, USA

Scandinavian ChemoTech och vd Mohan Frick kommer att presentera bolagets tumörspecifika elektroporation (TSE) vid LSI Emerging Medtech Summit 2023 i Kalifornien, USA. Evenemanget för samman medtech-branschens toppstrateger, investerare och innovatörer.

Read more

Redeye initierar analys av ChemoTech – ser stor potential vid klinisk validering

Redeye initierar bevakning av Scandinavian ChemoTech AB, ("ChemoTech") och sätter ett motiverat värde på 9 kronor i basscenariot. Redeye flaggar dock för en kraftig omvärdering om den kliniska valideringen från AIIMS-studien i Jodhpur och Ulis-sjukhuset i Ukraina faller väl ut. Även det potentiella distributionsavtalet med Avante för vetIQure i USA nämns som en viktig trigger.

Read more

Scandinavian ChemoTech AB (publ) genomför en riktad nyemission och tillförs cirka 2,02 MSEK

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, AUSTRALIEN, HONGKONG, NYA ZEELAND, SYDAFRIKA, SYDKOREA, SCHWEIZ, SINGAPORE, JAPAN, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDANT OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION INTE SKULLE VARA FÖRENLIG MED TILLÄMPLIGA REGLER ELLER KRÄVA REGISTRERING ELLER LIKNANDE ÅTGÄRDER.

Read more

News & Press Releases English

Scandinavian ChemoTech participates and presents at the LSI Emerging Medtech Summit in California, USA

Scandinavian ChemoTech and CEO Mohan Frick will present the company's tumor-specific electroporation (TSE) at the LSI Emerging Medtech Summit 2023 in California, USA. The event brings together the medtech industry's top strategists, investors and innovators.

Read more

Scandinavian ChemoTech AB (publ) carries out a directed share issue and receives approximately 2.02 MSEK

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, JAPAN, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISCLOSURE, PUBLICATION OR DISTRIBUTION WOULD NOT COMPLY WITH APPLICABLE REGULATIONS OR REQUIRE REGISTRATION OR…

Read more

Pancreatic cancer patients in Ukraine treated with TSE continues to have a good quality of life

Scandinavian ChemoTech has received encouraging updated information from Ulis Hospital Ukraine, which states that the performance status of the treated pancreatic cancer patients continues to be good close to six months after treatment.

Read more

ChemoTech Videos

2023

Redeye Investor Forum - Company Presentation

Clinical strategy update from Medical Director Dr. Suhail Mufti

Redeye Fight Cancer Day 2023 - ChemoTech

2022

ChemoTech 2022 - Mohan Frick CEO summarises the year (Swedish)

ChemoTech Q2 2022 - Livestream Presentation (in Swedish)

SWECARE at EXPO 2020 DUBAI: "Closing Ceremony"

A conversation with Småbolagspodden

(Audio in Swedish)

I det senaste avsnittet av Småbolagspodden berättar Scandinavian ChemoTechs vd Mohan Frick om hur bolagets unika metod för cancerbehandling, via så kallad tumörspecifik elektroporation, ska hjälpa människor och djur världen över.

Lyssna på hela avsnittet här:
52. ChemoTech – Vill vara en kraft för skonsammare cancervård

2021

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Videos from 2020

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in electroporation forms the starting point for the company’s existing product and R&D projects: The IQwave™ specially designed for our TSE™ – Tumour Specific Electroporation technology which treats a range of various tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.